Cristina Carames
Overview
Explore the profile of Cristina Carames including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
535
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carames C, Arcos J, Pfang B, Cristobal I, Antonio Alvaro J
Health Policy
. 2025 Jan;
152:105249.
PMID: 39813829
No abstract available.
2.
Carames C, Arcos J, Pfang B, Cristobal I, Alvaro de la Parra J
Front Public Health
. 2024 Nov;
12:1484709.
PMID: 39507667
Controversy surrounds the current debate regarding the effects of outsourcing health services, as recent studies claim that increased outsourcing leads to reduced costs at the expense of worse patient outcomes....
3.
Garcia-Miguel J, Yankova Komsalova L, Mata Arnaiz C, Alegre-Sancho J, Gonzalez Polo J, Torrente-Segarra V, et al.
Curr Med Res Opin
. 2024 Jun;
40(8):1431-1438.
PMID: 38932718
Objective: MSB11022 is a biosimilar of adalimumab that has been shown comparable bioequivalence, safety, tolerability, and immunogenicity profiles to the reference adalimumab in healthy volunteers or in patients with psoriasis...
4.
Santos A, Cristobal I, Carames C, Luque M, Sanz-Alvarez M, Madoz-Gurpide J, et al.
Int J Mol Sci
. 2023 May;
24(9).
PMID: 37175484
MicroRNA (miR)-19b is deregulated in colorectal cancer (CRC) and locally advanced rectal cancer (LARC), predicting worse outcome and disease progression in CRC patients, and acting as a promising prognostic marker...
5.
Santos A, Cristobal I, Rubio J, Carames C, Luque M, Sanz-Alvarez M, et al.
Int J Mol Sci
. 2022 Oct;
23(20).
PMID: 36293302
The standard clinical management of locally advanced rectal cancer (LARC) patients includes neoadjuvant 5-fluorouracil (5-FU)-based chemoradiotherapy (CRT) followed by mesorectal excision. MicroRNA (miR)-19b expression levels in LARC biopsies obtained from...
6.
Santos A, Cristobal I, Rubio J, Carames C, Luque M, Sanz-Alvarez M, et al.
Int J Mol Sci
. 2022 Feb;
23(4).
PMID: 35216319
The identification of robust prognostic markers still represents a need in locally advanced rectal cancer (LARC). MicroRNAs (miRs) have progressively emerged as promising circulating markers, overcoming some limitations that traditional...
7.
Guadalajara H, Lopez-Fernandez O, Leon Arellano M, Dominguez-Prieto V, Carames C, Garcia-Olmo D
Pharmaceuticals (Basel)
. 2022 Feb;
15(2).
PMID: 35215327
Surgeons and cancer patients are starting to open the debate on how personalised medicine could use shared decision-making (SDM) to balance the personal and clinical components and thus improve the...
8.
Ruiz Hispan E, Pedregal M, Cristobal I, Garcia-Foncillas J, Carames C
J Clin Med
. 2021 Oct;
10(20).
PMID: 34682772
Peritoneal metastases from gastric cancer play a key role in the fatal prognosis of the disease. The lack of efficacy of actual therapeutic approaches together with the outcomes achieved with...
9.
Cristobal I, Santos A, Rubio J, Carames C, Zazo S, Sanz-Alvarez M, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638487
The absence of established predictive markers with value to anticipate response to neoadjuvant 5-fluorouracil (5-FU)-based chemoradiotherapy (CRT) represents a current major challenge in locally advanced rectal cancer (LARC). The tumor...
10.
Rubio J, Cristobal I, Santos A, Carames C, Luque M, Sanz-Alvarez M, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33810186
The standard treatment for patients with locally advanced colorectal cancer (LARC) is neoadjuvant 5-fluorouracil (5-FU) based chemoradiotherapy (CRT) followed by surgical mesorectal excision. However, the lack of response to this...